TGA / PMDA / NMPA · Asia-Pacific
derivative — TGA / PMDA / NMPA regulatory status
derivative regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 3 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| 1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative | Phase 2 | Chinese Academy of | NCT02329730 |
| Spray of spirulina derivatives | Phase 2 | Chinese Academy of | NCT07040969 |
| Purified Protein Derivative of BCG（BCG-PPD） | Phase 1 | Anhui Huaheng Biotechnology | NCT06975774 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 20260146049 | SPIROCYCLIC ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | US |
| 2024342196 | NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF | AU |
| 2024268154 | NOVEL CARBOXAMIDE DERIVATIVES | AU |
| 12428403 | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists | US |
| 12428408 | Fused heterocyclic mescaline derivatives | US |
| 12421228 | Naphthyridine derivatives as PRC2 inhibitors | US |
| 12421236 | Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor | US |
| 12421231 | Azaindole derivatives and their use as ERK kinase inhibitors | US |
| 12404237 | Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives | US |
| 12403136 | Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof | US |
| 12398179 | Nanomolar peptides and derivatives to differentially modulate ephrin receptors | US |
| 12396989 | Nicorandil derivatives | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of derivative?
derivative currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get derivative regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to derivative?
This spoke lists 3 published programs associated with derivative in our pipeline index.